share_log

Further Weakness as Zai Lab (NASDAQ:ZLAB) Drops 8.9% This Week, Taking Three-year Losses to 61%

Further Weakness as Zai Lab (NASDAQ:ZLAB) Drops 8.9% This Week, Taking Three-year Losses to 61%

再鼎醫藥(納斯達克:ZLAB)本週下跌8.9%進一步走弱,三年損失達到61%。
Simply Wall St ·  12/16 18:51

Zai Lab Limited (NASDAQ:ZLAB) shareholders should be happy to see the share price up 27% in the last quarter. But over the last three years we've seen a quite serious decline. Regrettably, the share price slid 61% in that period. So the improvement may be a real relief to some. While many would remain nervous, there could be further gains if the business can put its best foot forward.

再鼎醫藥有限公司(納斯達克:ZLAB)股東應該會對股價在上個季度上漲27%感到高興。 但在過去三年中,我們看到股價有相當嚴重的下滑。 不幸的是,在此期間股價下跌了61%。 所以這種改善可能對一些人來說是一個真正的 relief。 雖然許多人可能會保持緊張,但如果業務能夠盡善盡美,可能還有進一步的漲幅。

With the stock having lost 8.9% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.

由於股票在過去一週下跌了8.9%,值得關注一下業務表現,看看是否有任何風險信號。

Zai Lab isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

再鼎醫藥目前尚未盈利,因此大多數分析師會關注營收增長,以了解基礎業務增長的速度。 不盈利公司的股東通常希望看到強勁的營業收入增長。 這是因爲如果營業收入增長微不足道且公司從未盈利,很難對公司可持續性感到自信。

In the last three years, Zai Lab saw its revenue grow by 31% per year, compound. That is faster than most pre-profit companies. The share price has moved in quite the opposite direction, down 17% over that time, a bad result. It seems likely that the market is worried about the continual losses. When we see revenue growth, paired with a falling share price, we can't help wonder if there is an opportunity for those who are willing to dig deeper.

在過去三年中,再鼎醫藥的營業收入年均增長31%。 這比大多數未盈利公司要快。 在這段時間內,股價卻大幅下跌了17%,結果不佳。 看起來市場擔心持續的虧損。 當我們看到營業收入增長而股價下跌時,我們不禁想知道是否對願意深入研究的人來說存在機會。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到盈利和營業收入隨時間的變化(通過點擊圖片發現確切值)。

big
NasdaqGM:ZLAB Earnings and Revenue Growth December 16th 2024
納斯達克GM:ZLAB盈利和營業收入增長 2024年12月16日

Zai Lab is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. If you are thinking of buying or selling Zai Lab stock, you should check out this free report showing analyst consensus estimates for future profits.

再鼎醫藥是一隻知名的股票,受到衆多分析師的關注,這表明未來增長有一定的可見性。如果你正在考慮買入或賣出再鼎醫藥的股票,你應該查看這份免費的報告,報告中顯示了分析師對未來利潤的共識估計。

A Different Perspective

不同的視角

While the broader market gained around 30% in the last year, Zai Lab shareholders lost 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Zai Lab better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Zai Lab you should know about.

雖然大盤在過去一年上漲了約30%,但再鼎醫藥的股東卻損失了12%。然而,請注意,即便是最好的股票,有時在一年內也可能會表現不佳。不幸的是,去年的表現可能表明存在未解決的挑戰,因爲其表現甚至低於過去五年年化損失的6%。一般而言,長期的股價疲弱可能是一個不好的信號,儘管逆向投資者可能希望研究這隻股票,期待其反彈。追蹤股價在更長期內的表現總是很有趣。但要更好地理解再鼎醫藥,我們需要考慮許多其他因素。比如,考慮風險。每家公司都有風險,而我們發現再鼎醫藥有1個警示信號,你應該了解。

We will like Zai Lab better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

如果我們看到一些大額內部人士買入,我們會更喜歡再鼎醫藥。在我們等待的同時,請查看這份免費的低估股票列表(主要是小型股),這些股票最近有相當大的內部人士買入。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論